LifeSpan Vision Ventures – an investment firm that funds longevity biotech breakthroughs – recently announced an investment in Bolden Therapeutics. This biotechnology company is developing first-in-class therapeutics to promote neurogenesis to treat central nervous system diseases potentially.
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases. The company’s scientific co-founders, Dr. Justin Fallon and Dr. Ashley Webb, have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. The company is now working on antisense oligonucleotides for this genetically validated target, with candidates ready for in vivo efficacy testing.
Bolden’s research facilities are based within Tufts Launchpad | biolabs, which is a leading incubator for next-generation powerhouse biotech startups located in Boston, MA. Before moving to biolabs, Bolden was based at LabCentral and its tenure was supported by two ‘Golden Tickets’ from Biogen, providing the company with two years of sponsored laboratory space within that innovative ecosystem.
KEY QUOTES:
“We’re excited to partner with Bolden Therapeutics and enthusiastic about the potential of their promising results in advancing treatment options for Alzheimer’s disease and other age-related neurodegenerative conditions. With a robust team and Scientific Advisory Board, we are eager to support Bolden’s mission to enhance the lives of millions affected by neurological diseases through the development of therapies that boost neurogenesis.”
— Andrew Worden, Founding Partner at LifeSpan Vision Ventures
“We are extremely excited to have Lifespan Vision Ventures as part of Team Bolden. The next several months are a crucial time for the company and Lifespan’s partnership represents a fantastic step towards achieving our goal of developing therapies to combat neurological diseases.”
— Johnny Page, co-founder and CEO of Bolden Therapeutics
